<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999764</url>
  </required_header>
  <id_info>
    <org_study_id>RET IDA 02</org_study_id>
    <nct_id>NCT01999764</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation</brief_title>
  <official_title>Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QLT Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QLT Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IIa proof-of-concept study to evaluate the effects of oral QLT091001 on
      adults with impaired dark adaptation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proof-of-concept study is a randomized, parallel design of two different oral doses of
      QLT091001 compared to placebo to evaluate treatment effects in patients with impaired dark
      adaptation.

      Approximately 40 subjects will be enrolled in this study at approximately 7 centers in the
      US.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Through 7 weeks</time_frame>
    <description>Low luminance low contrast best-corrected visual acuity (LLLC BCVA) will be measured at multiple time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dark Adaptation Time</measure>
    <time_frame>Through 7 weeks</time_frame>
    <description>Dark Adaptation Time will be measured at multiple time points.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Glare Recovery</measure>
    <time_frame>Through 7 weeks</time_frame>
    <description>Glare recovery time will be measured at multiple time points.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Impaired Dark Adaptation</condition>
  <arm_group>
    <arm_group_label>Placebo (for QLT091001)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is supplied to mimic QLT091001 oral solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QLT091001 - first oral dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an oral dose of 10mg/m2 of QLT091001.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QLT091001 - second oral dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an oral dose of 40 mg/m2 of QLT091001.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QLT091001</intervention_name>
    <description>QLT091001 administered orally at multiple time points.</description>
    <arm_group_label>QLT091001 - first oral dose</arm_group_label>
    <arm_group_label>QLT091001 - second oral dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered orally at multiple time points.</description>
    <arm_group_label>Placebo (for QLT091001)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects â‰¥60 yrs with early age-related macular degeneration (AMD)
             based on LLLC BCVA criterion or evidence of impaired dark adaptation

          -  Subjects with high luminance high contrast best-corrected visual acuity (HLHC BCVA) of
             40 letters (20/40 Snellen) or better in the study eye

          -  Capable and willing to provide consent

        Exclusion Criteria:

          -  Women of child bearing potential

          -  Subjects with late AMD or any other optic neuropathy in the study eye

          -  Subjects with posterior subcapsular cataract or multifocal intra-ocular lens (IOL) in
             the study eye

          -  Subjects who are actively participating in an experimental therapy study or who have
             received experimental therapy within 60 days of Day 0 or who have taken any
             prescription/investigational oral retinoid medication within 6 months of Day 0

          -  Subjects taking age-related eye disease study (AREDS) supplements containing
             beta-carotene
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sushanta Mallick, Ph.D MBA</last_name>
    <role>Study Director</role>
    <affiliation>QLT Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sall Research Medical Center</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keystone Research Ltd.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Proliance Surgeons Inc.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <disposition_first_submitted>June 16, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>June 16, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 14, 2015</disposition_first_posted>
  <last_update_submitted>June 16, 2015</last_update_submitted>
  <last_update_submitted_qc>June 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinol acetate</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

